

31

provide 100 inhalations of the composition of the invention. Each container is provided with the following:

Compound A	0.0120 g
trichloromonofluoromethane	1.6939 g
dichlorodifluoromethane	3.7175 g
dichlorotetrafluoroethane	1.5766 g
total	7.0000 g

While the invention has been described with respect to the particular embodiments, it will be apparent to those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention as defined in the claims. Such modifications are also intended to fall within the scope of the appended claims.

The invention claimed is:

1. A method of treating depression, inflammatory skin disease, psoriasis, atopic dermatitis, contact dermatitis, rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, inflammatory bowel disease, Crohn's Disease, Behcet's Disease or colitis, which comprises administering to a patient in need of such treatment a therapeutically effective amount of stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 further comprising administering to a patient in need of such treatment a therapeutically effective amount of an antihistamine, anti-inflammatory drug, non-steroid anti-inflammatory drug, or steroid.

3. The method of claim 1 wherein the patient is a mammal.

4. The method of claim 1 wherein the stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione is administered parenterally, transdermally, mucosally, nasally, buccally, sublingually, or orally.

5. The method of claim 4 wherein the stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione is administered orally.

6. The method of claim 5 wherein the stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonyl-

32

ethyl]-4-acetylaminoisoindoline-1,3-dione is administered orally in a tablet or capsule form.

7. The method of claim 1 wherein the therapeutically effective amount is from about 1 mg to about 1000 mg per day.

8. The method of claim 7 wherein the therapeutically effective amount is from about 5 mg to about 500 mg per day.

9. The method of claim 8 wherein the therapeutically effective amount is from about 10 mg to about 200 mg per day.

10. A method of treating psoriasis which comprises administering to a patient having psoriasis a therapeutically effective amount of stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione.

11. The method of claim 10, wherein the stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione is substantially free of (-) isomer.

12. The method of claim 10, wherein the compound is administered orally.

13. The method of claim 12, wherein the compound is administered in the form of a tablet or capsule.

14. The method of claim 10, wherein the compound is administered in the amount of from about 1 mg to about 1,000 mg per day.

15. The method of claim 14, wherein the compound is administered in the amount of from about 5 mg to about 500 mg per day.

16. The method of claim 15, wherein the compound is administered in the amount of from about 10 mg to about 200 mg per day.

17. The method of claim 16, wherein the compound is administered in the amount of about 20 mg to about 40 mg per day.

18. The method of claim 17, wherein the compound is administered in the amount of about 20 mg twice daily.

19. The method of claim 17, wherein the compound is administered in the amount of about 40 mg once daily.

20. The method of claim 10, further comprising administering to a patient in need of such treatment a therapeutically effective amount of an antihistamine, anti-inflammatory drug, non-steroid anti-inflammatory drug, or steroid.

\* \* \* \* \*